Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 May;17(5):741-8.
doi: 10.1517/13543784.17.5.741.

Axitinib for renal cell carcinoma

Guru Sonpavde  1 , Thomas E Hutson, Brian I Rini
Affiliations
Review

Axitinib for renal cell carcinoma

Guru Sonpavde et al. Expert Opin Investig Drugs. 2008 May.

Erratum in

  • Expert Opin Investig Drugs. 2008 Sep;17(9):1405

Abstract

Background: The approval of sunitinib, sorafenib and temsirolimus has dramatically altered the management of renal cell carcinoma (RCC). Bevacizumab plus IFN may also be added to the therapeutic armamentarium. Axitinib (AG-013736) is an oral and selective tyrosine kinase inhibitor.

Objective: Data supporting the development of axitinib for RCC are reviewed.

Methods: Preclinical and clinical data available for axitinib for RCC are presented.

Results: Axitinib inhibits VEGFR-1, VEGFR-2 and VEGFR-3 with picomolar potencies, and PDGFR-alpha, PDGFR-beta and c-kit with nanomolar potencies. Phase II clinical trials of axitinib in pretreated RCC following sorafenib or cytokine treatment have demonstrated promising activity accompanied by a favorable toxicity profile. Further development of axitinib for RCC is warranted.

PubMed Disclaimer

MeSH terms

LinkOut - more resources